[CAS NO. 405168-58-3]  CHIR-124

Ships within Stock Price Qty Total
$0.00
$0.00
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [405168-58-3]

Store
Catalog
SLK-S2683
Brand
Selleck
CAS
405168-58-3

DESCRIPTION [405168-58-3]

Overview

MDLMFCD14636453
Molecular Weight419.91
Molecular FormulaC23H22ClN5O
SMILESO=C1NC2=C(C=C(Cl)C=C2)C(N[C@@H]3CN4CCC3CC4)=C1C5=NC6=CC=CC=C6N5

For research use only.

Storage

3 years,-20°C,powder
1 years,-80°C,in solvent

Shipping

Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)

Description

CHIR-124 is a novel and potent inhibitor with of 0.3 nM in a cell-free assay. It shows 2,000-fold selectivity against Chk2, 500- to 5,000-fold less activity against CDK2/4 and Cdc2.

Targets

Chk1 [1]
(Cell-free assay)
FLT3 [1]
(Cell-free assay)
PDGFR [1]
(Cell-free assay)
GSK-3 [1]
(Cell-free assay)
0.3 nM5.8 nM6.6 nM23.3 nM

In vitro

CHIR-124 is a quinolone-based small molecule that is structurally unrelated to other known inhibitors of Chk1. CHIR-124 interacts synergistically with topoisomerase poisons (e.g., Camptothecin or SN-38) in causing growth inhibition in a variety of cancer cell lines, including breast carcinoma (MDA-MB-231 and MDA-MB-435) and colon carcinoma (SW-620 and Colo205), all of which contains the mutant p53 gene. CHIR-124 abrogates the SN-38-induced S and G2-M checkpoints and potentiates apoptosis in MDA-MD-435 breast cancer cells. The abrogation of the G2-Mcheckpoint and induction of apoptosis by CHIR-124 are enhanced by the loss of p53. CHIR-124 also potently targets other kinases such as PDGFR and Flt3 with IC50 of 6.6 nM and 5.8 nM, respectively.

In vivo

CHIR-124 potentiates the growth inhibitory effects of Irinotecan by abrogating the G-M checkpoint and increasing tumor apoptosis in an orthotopic breast cancer xenograft model.